Detalimogene Voraplasmid · EG-70

What is Detalimogene Voraplasmid?

Detalimogene voraplasmid is a non-viral plasmid DNA vector encoding interleukin-12 and a RIG-I activating moiety, encapsulated in chitosan nanoparticles for intravesical delivery to the bladder urothelium. It drives local IL-12 expression and RIG-I signaling, activating natural killer cells, cytotoxic T lymphocytes and interferon responses. It is studied in superficial and non-muscle invasive bladder cancer, including carcinoma in situ.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

EG-70, Phase 2, Phase 1

Drug type

Vaccine (DNA plasmid)

Targets

RIG-I

Mechanism

Immune activation, directed at RIG-I

Pathways

RIG-I-mediated interferon signaling, NK cell activation, cytotoxic T-lymphocyte response, apoptosis of cancer cells

Therapy area

Oncology

Developer

enGene, Inc. (ENGN)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

UNII

X3KB597LMN

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-muscle Invasive Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT04752722
• ClinicalTrials.gov NCT04752722

Updated Oct 11, 2026. Something wrong or missing? Report it on the ENGN page.